Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ChromaDex Corporation - Common Stock (NQ:CDXC)

7.870 UNCHANGED
Last Price Updated: 4:00 PM EDT, Mar 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about ChromaDex Corporation - Common Stock

< Previous 1 2 3 4 Next >
News headline image
ChromaDex Announces Agreement to Launch Commercial Joint Venture in Mainland China
From ChromaDex Corporation
Via Business Wire
News headline image
ChromaDex Wins International 2022 European NutraIngredients Award for Developing the Science Behind Niagen®
From ChromaDex Corporation
Via Business Wire
News headline image
ChromaDex Corporation Reports First Quarter 2022 Financial Results
From ChromaDex Corporation
Via Business Wire
News headline image
ChromaDex to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022
From ChromaDex Corporation
Via Business Wire
News headline image
ChromaDex Appoints Ann Cohen and Kristin Patrick to its Board of Directors
From ChromaDex Corporation
Via Business Wire
News headline image
ChromaDex External Research Program (CERP™) Celebrates Over 250 Research Agreements With 235+ Researchers Around the World
From ChromaDex Corporation
Via Business Wire
News headline image
ChromaDex Launches Tru Niagen® Immune, Further Expanding Innovative Product Portfolio
From ChromaDex Corporation
Via Business Wire
News headline image
ChromaDex Announces Issuance of Additional New U.S. Continuation Patent, Further Protecting Future Innovations
From ChromaDex Corporation
Via Business Wire
News headline image
ChromaDex to Report Fourth Quarter 2021 Financial Results on Wednesday, March 9, 2022
From ChromaDex Corporation
Via Business Wire
News headline image
ChromaDex Announces Issuance of New U.S. Continuation Patent, Expanding Intellectual Property Portfolio for Nicotinamide Riboside
From ChromaDex Corporation
Via Business Wire
News headline image
ChromaDex External Research Program (CERP™) Celebrates 100 Peer-Reviewed Published Studies on Niagen® and Other Ingredients
From ChromaDex Corporation
Via Business Wire
News headline image
ChromaDex Announces Results of New Pilot Clinical Trial Showing Anti-Inflammatory Effects of Nicotinamide Riboside (NR) Supplementation
From ChromaDex Corporation
Via Business Wire
News headline image
ChromaDex and Designs for Health Partner for New Product Development on Niagen®
From ChromaDex Corporation
Via Business Wire
News headline image
ChromaDex Corporation Reports Third Quarter 2021 Financial Results
From ChromaDex Corporation
Via Business Wire
News headline image
ChromaDex Shares Findings from First Clinical Study on Nicotinamide Riboside (NR) in Children, Highlighting Improvements for Prematurely Aging Patients with Ataxia-Telangiectasia (AT)
From ChromaDex Corporation
Via Business Wire
News headline image
ChromaDex to Report Third Quarter 2021 Financial Results on Wednesday, Nov. 3, 2021
From ChromaDex Corporation
Via Business Wire
News headline image
ChromaDex Comments on Jury Award Against Elysium Health and Reiterates Plans for Growth
From ChromaDex Corporation
Via Business Wire
News headline image
ChromaDex Partners with Sinopharm Xingsha for Cross-Border Sales of Tru Niagen® into Mainland China
From ChromaDex Corporation
Via Business Wire
News headline image
ChromaDex Shares Preclinical Research Findings and Scientific Initiations from the ChromaDex External Research Program (CERP™)
From ChromaDex Corporation.
Via Business Wire
News headline image
ChromaDex Continues to Defend Strong Intellectual Property Portfolio and Plans to Appeal Judge’s Ruling in Patent Infringement Lawsuit
From ChromaDex Corporation
Via Business Wire
News headline image
ChromaDex Corporation Reports Second Quarter 2021 Financial Results
From ChromaDex Corporation
Via Business Wire
News headline image
ChromaDex to Report Second Quarter 2021 Financial Results on Tuesday, August 3, 2021
From ChromaDex Corporation
Via Business Wire
News headline image
ChromaDex Shares Research Findings from the ChromaDex External Research Program (CERP™)
From ChromaDex Corporation
Via Business Wire
News headline image
ChromaDex and Walmart Launch Tru Niagen® in 3,800 Walmart Stores Across the United States
From ChromaDex Corporation
Via Business Wire
News headline image
ChromaDex Corporation Reports First Quarter 2021 Financial Results
From ChromaDex Corporation
Via Business Wire
News headline image
ChromaDex and Ro Partner for New Product Development
From ChromaDex Corporation
Via Business Wire
News headline image
ChromaDex to Present at Benzinga’s Global Small Cap Conference on May 13, 2021
From ChromaDex Corporation
Via Business Wire
News headline image
ChromaDex to Report First Quarter 2021 Financial Results on Thursday, May 6, 2021
From ChromaDex Corporation
Via Business Wire
News headline image
ChromaDex and Health & Happiness (H&H) Group Announce Supply Agreement for Niagen®
From ChromaDex Corporation
Via Business Wire
News headline image
ChromaDex Appoints Fadi Karam as Chief Marketing Officer
From ChromaDex Corporation
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.